FNY Partners Fund LP increased its position in GW Pharmaceuticals PLC (NASDAQ:GWPH) by 46.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,700 shares of the biopharmaceutical company’s stock after acquiring an additional 1,800 shares during the period. FNY Partners Fund LP’s holdings in GW Pharmaceuticals PLC were worth $571,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in GWPH. BNP Paribas Arbitrage SA purchased a new position in GW Pharmaceuticals PLC in the 2nd quarter worth approximately $163,000. Quantitative Systematic Strategies LLC purchased a new stake in GW Pharmaceuticals PLC during the 2nd quarter valued at $204,000. Blair William & Co. IL purchased a new stake in GW Pharmaceuticals PLC during the 1st quarter valued at $207,000. Cambridge Investment Research Advisors Inc. purchased a new stake in GW Pharmaceuticals PLC during the 2nd quarter valued at $213,000. Finally, Ameriprise Financial Inc. purchased a new stake in GW Pharmaceuticals PLC during the 1st quarter valued at $230,000. Institutional investors own 75.07% of the company’s stock.
GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down 0.33% during midday trading on Monday, hitting $107.22. The stock had a trading volume of 62,378 shares. The firm’s market capitalization is $2.72 billion. The firm has a 50-day moving average of $106.85 and a 200 day moving average of $110.52. GW Pharmaceuticals PLC has a 52-week low of $92.65 and a 52-week high of $137.88.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.73) by $0.34. GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. The company had revenue of $3.14 million during the quarter, compared to analyst estimates of $2.10 million. During the same quarter in the previous year, the company posted ($0.05) EPS. On average, equities analysts forecast that GW Pharmaceuticals PLC will post ($5.94) EPS for the current year.
A number of equities research analysts have weighed in on GWPH shares. BidaskClub upgraded shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $119.00 target price for the company in a research note on Monday, July 17th. Maxim Group set a $135.00 target price on shares of GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Thursday, June 8th. Leerink Swann reiterated an “outperform” rating and set a $160.00 target price (down from $162.00) on shares of GW Pharmaceuticals PLC in a research note on Thursday, August 10th. Finally, ValuEngine upgraded shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. GW Pharmaceuticals PLC presently has an average rating of “Buy” and an average price target of $148.55.
COPYRIGHT VIOLATION WARNING: “GW Pharmaceuticals PLC (GWPH) Position Boosted by FNY Partners Fund LP” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/09/11/gw-pharmaceuticals-plc-gwph-position-boosted-by-fny-partners-fund-lp.html.
About GW Pharmaceuticals PLC
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.